<DOC>
	<DOCNO>NCT00922090</DOCNO>
	<brief_summary>The primary objective NIS ass clinical benefit subject derive take seroquel XR , use CGI-CB . The secondary objective ass effectiveness , safety tolerability seroquel XR tablet .</brief_summary>
	<brief_title>A Non-interventional Study Evaluating Clinical Benefit Effectiveness Quetiapine Fumarate Extended</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Diagnosed Schizophrenia accord DSMIVTR criterion Patients take Seroquel XR longer 1 month Patients get antipsychotic monotherapy least 1 week enroll study First episode , drug naive schizophrenic subject . Meeting criterion ( schizophrenia ) DSMIV Axis I diagnosis , concomitant organic mental disorder mental retardation opinion Principal Investigator may interfere study conduct interpretation . Known lack response clozapine treatment clozapine within 4 week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Seroquel XR</keyword>
	<keyword>CGI-CB</keyword>
	<keyword>SWN-K</keyword>
</DOC>